clinical trial · NCT07532213
A Study to Assess Real-world Outcomes for Long-Term Use of Guselkumab
Janssen-Cilag A.G., Switzerland·—·not yet recruiting·n = 50
Inflammatory Bowel DiseaseColitis, UlcerativeCrohn Disease
brief summary
The purpose of this study is to evaluate how long guselkumab remains in participants with moderate to severe crohn's disease (CD) or ulcerative colitis (UC) in real-world setting. CD and UC are Inflammatory bowel disease, a group of inflammatory conditions of the colon and small intestine.
started
Apr 23, 2026
primary completion
Apr 10, 2029
completion
Apr 10, 2029
last updated
Apr 15, 2026
official title
Long-Term Use of Guselkumab: Non-interventional Assessment of Real-world Outcomes
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol